No risk reduction for Plasmodium vivax malaria in sickle cell disease

Bushra Moiz; Ayesha Majeed

doi:10.1002/ccr3.1507

No risk reduction for Plasmodium vivax malaria in sickle cell disease

Bushra Moiz
, Ayesha Majeed

Department of Pathology and Laboratory Medicine, Medical College, Pakistan

Research output: Contribution to journal › Comment/debate

1 Citation (Scopus)

Abstract

Hemoglobin S is known to protect against uncomplicated Plasmodium falciparum malaria. However, there is paucity of the literature regarding interaction of HbS and other malaria species. Usually, P. vivax malaria is a relapsing condition, and without radical cure with primaquine, recurrence may be observed even with hemoglobin S.

Original language	English (US)
Pages (from-to)	1187-1188
Number of pages	2
Journal	Clinical Case Reports
Volume	6
Issue number	6
DOIs	https://doi.org/10.1002/ccr3.1507
Publication status	Published - Jun 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Hemoglobinopathy
malaria
sickle cell disease
vivax malaria

Access to Document

10.1002/ccr3.1507

Cite this

@article{d0649bd98fd646c6853df27eaef8a1cb,

title = "No risk reduction for Plasmodium vivax malaria in sickle cell disease",

abstract = "Hemoglobin S is known to protect against uncomplicated Plasmodium falciparum malaria. However, there is paucity of the literature regarding interaction of HbS and other malaria species. Usually, P. vivax malaria is a relapsing condition, and without radical cure with primaquine, recurrence may be observed even with hemoglobin S.",

keywords = "Hemoglobinopathy, malaria, sickle cell disease, vivax malaria",

author = "Bushra Moiz and Ayesha Majeed",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors. Clinical Case Reports published by John Wiley \& Sons Ltd.",

year = "2018",

month = jun,

doi = "10.1002/ccr3.1507",

language = "English (US)",

volume = "6",

pages = "1187--1188",

journal = "Clinical Case Reports",

issn = "2050-0904",

publisher = "John Wiley and Sons Ltd",

number = "6",

}

TY - JOUR

T1 - No risk reduction for Plasmodium vivax malaria in sickle cell disease

AU - Moiz, Bushra

AU - Majeed, Ayesha

PY - 2018/6

Y1 - 2018/6

N2 - Hemoglobin S is known to protect against uncomplicated Plasmodium falciparum malaria. However, there is paucity of the literature regarding interaction of HbS and other malaria species. Usually, P. vivax malaria is a relapsing condition, and without radical cure with primaquine, recurrence may be observed even with hemoglobin S.

AB - Hemoglobin S is known to protect against uncomplicated Plasmodium falciparum malaria. However, there is paucity of the literature regarding interaction of HbS and other malaria species. Usually, P. vivax malaria is a relapsing condition, and without radical cure with primaquine, recurrence may be observed even with hemoglobin S.

KW - Hemoglobinopathy

KW - malaria

KW - sickle cell disease

KW - vivax malaria

UR - https://www.scopus.com/pages/publications/85050038927

U2 - 10.1002/ccr3.1507

DO - 10.1002/ccr3.1507

M3 - Comment/debate

AN - SCOPUS:85050038927

SN - 2050-0904

VL - 6

SP - 1187

EP - 1188

JO - Clinical Case Reports

JF - Clinical Case Reports

IS - 6

ER -

No risk reduction for Plasmodium vivax malaria in sickle cell disease

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this